IXP
Phase 1Completed 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Focal Segmental Glomerulosclerosis (FSGS)
Conditions
Focal Segmental Glomerulosclerosis (FSGS)
Trial Timeline
Aug 2, 2024 → Dec 20, 2024
NCT ID
NCT06529796About IXP
IXP is a phase 1 stage product being developed by Vertex Pharmaceuticals for Focal Segmental Glomerulosclerosis (FSGS). The current trial status is completed. This product is registered under clinical trial identifier NCT06529796. Target conditions include Focal Segmental Glomerulosclerosis (FSGS).
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06529796 | Phase 1 | Completed |
| NCT05865171 | Phase 1 | Completed |
Competing Products
20 competing products in Focal Segmental Glomerulosclerosis (FSGS)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| OnabotulinumtoxinA 145 UNT [Botox] | AbbVie | Approved | 85 |
| Dapagliflozin | AstraZeneca | Approved | 85 |
| Enfuvirtide + Tenofovir-Emtricitabine | Roche | Phase 2 | 52 |
| CCX140-B | Amgen | Phase 2 | 51 |
| PF-06730512 | Pfizer | Phase 2 | 51 |
| Gabapentin, Lamotrigine, Levetiracetam, Pregabalin, Oxcarbacepine, Tiagabine, Topiramate, Zonisamide | Pfizer | Approved | 84 |
| VX-147 | Vertex Pharmaceuticals | Phase 2 | 51 |
| VX-147 | Vertex Pharmaceuticals | Phase 1 | 32 |
| fresolimumab + fresolimumab + Placebo | Sanofi | Phase 2 | 51 |
| GC1008 + GC1008 + GC1008 + GC1008 | Sanofi | Phase 1 | 32 |
| frexalimab + brivekimig + rilzabrutinib + placebo | Sanofi | Phase 2 | 51 |
| Vivaglobin | CSL | Phase 2 | 51 |
| UCB0942 | UCB | Phase 2 | 49 |
| Levetiracetam + Carbamazepine + Lamotrigine | UCB | Approved | 82 |
| Brivaracetam + Brivaracetam | UCB | Phase 2 | 49 |
| Lacosamide | UCB | Phase 2 | 49 |
| UCB0942 + UCB0942 + Placebo | UCB | Phase 2 | 49 |
| Lacosamide | UCB | Pre-clinical | 20 |
| ARGX-117 | Argenx | Phase 2 | 49 |
| Empasiprubart + IVIG (Intravenous Immunoglobulin) | Argenx | Phase 3 | 74 |